Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

NCT00425373 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

1474

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Valsartan + amlodipine 40/2.5 mg
DRUG: Valsartan + amlodipine 40/5 mg
DRUG: Valsartan + amlodipine 80/2.5 mg
DRUG: Valsartan + amlodipine 80/5 mg
DRUG: Valsartan 40 mg
DRUG: Valsartan 80 mg
DRUG: Amlodipine 2.5 mg
DRUG: Amlodipine 5 mg
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals